title: Ultraviolet recall associated with etoposide and cyclophosphamide therapy.
abstract: Ultraviolet recall (UR) or sunburn reactivation is an infrequently reported phenomenon. It is characterized by an erythematous eruption in the distribution of previous ultraviolet-induced sunburn. The timing of the eruption correlates well with the speculation that it is induced by the administration of a chemotherapeutic agent(s). The case of a young man who developed UR after treatment with etoposide (VP16) and cyclophosphamide is reported.
authors.affiliation: Indiana University, School of Medicine, Indianapolis.
authors.forename: B J
authors.initials: BJ
authors.lastname: Williams
authors.forename: D J
authors.initials: DJ
authors.lastname: Roth
authors.forename: J P
authors.initials: JP
authors.lastname: Callen
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001761:Bleomycin / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects*; D003907:Dexamethasone / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D003875:Drug Eruptions / Q000209:etiology*; D005047:Etoposide / Q000009:adverse effects*; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects; D008297:Male; D008727:Methotrexate / Q000009:adverse effects; D011239:Prednisolone / Q000009:adverse effects; D012008:Recurrence; D013471:Sunburn / Q000209:etiology*; D014750:Vincristine / Q000009:adverse effects
chemical_list: D001761:Bleomycin; D014750:Vincristine; D005047:Etoposide; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D002955:Leucovorin; D008727:Methotrexate